TARDBP and myasthenia gravis: Importantly, these systems showed functional NMJ formation, measured skeletal fiber contractility, modeled axonal transport of pathophysiological TAR DNA binding protein 43 (TDP-43) in the case of ALS and could even induce a model of myasthenia gravis with patient-derived antibodies targeting NMJs.